menu

Aspergillosis Therapeutics Market

Schedule Call

Aspergillosis Therapeutics Market

Aspergillosis Therapeutics Market by Disease Type (Allergic Bronchopulmonary Aspergillosis, Aspergilloma, Chronic Pulmonary Aspergillosis, Invasive Aspergillosis, and Others), by Drug Class (Azole Antifungals, Antibiotics, Corticosteroids, and Others), and by Route of Administration (Oral, Parenteral, and Others) – Global Outlook & Forecast 2022-2030

GR - 665958 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: November 17, 2022

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Aspergillosis Therapeutics Market Scope

Report Attribute

Details

Market size value in 2021

US$ 2,914.10 million

Revenue forecast in 2030

US$ 4,424.77 million

Growth Rate

CAGR of 4.75% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Segments covered

by disease type, by drug class, by route of administration and region.

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

The global aspergillosis therapeutics market was pegged at US$ 2,914.10 million in 2021 and is expected to witness a CAGR of 4.75 % during the forecast period.

Market Fundamentals

Aspergillosis is a kind of fungal disease caused by aspergillus fumigatus member of genus aspergillus. The disease most commonly affects lungs but can spread to other parts of the body. Immunocompromised people are highly prone to acquire the disease. General symptoms associated with the disease include fever, night sweats, cough, fatigue, and unintended weight loss among others. The therapeutics for the disease include lipid amphoteric formulations, micafungin, caspofusgin, itraconazole, and isavuconazole. 

[878949]

Market Dynamic

People taking immunosuppressors after certain transplant surgeries such as bone marrow and stem cell transplant are at increased risk of acquiring the disease. In addition, people suffering from cancer have low WBC level which makes them more prone to acquire aspergillosis. Market players are introducing strategies like mergers and acquisition and introducing novel therapies to support market growth. The market is likely to show limited growth opportunities due to frequent expiration of antifungal drugs and declining prices due to increased industrial competition.            

Market Ecosystem

The global aspergillosis therapeutics market has been analyzed from four perspectives: by disease type, by drug class, by route of administration and region. 

Aspergillosis Therapeutics Market by Disease Type 

The global aspergillosis therapeutics market according to disease type is grouped into allergic bronchopulmonary aspergillosis, aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis, and others. Pulmonary aspergillosis dominated the market in 2021. Pulmonary aspergillosis is an allergic reaction by fungus. Rising prevalence of cystic fibrosis or asthma is increasing segmental growth along with prevalence of allergic bronchopulmonary. People with other lung disorders such as tuberculosis are also susceptible to aspergillomas. 

[632342]

Aspergillosis Therapeutics Market by Drug Class

According to drug class, the global aspergillosis therapeutics market is segmented into azole antifungals, antibiotics, corticosteroids, and others. Azole antifungals dominated the global aspergillosis therapeutics market in 2021. The advantages offered by azole such as long-lasting resistance by inhibiting production of ergosterol is increasing its demand. The only azole that is currently considered as the main treatment against aspergillosis is itraconazole. 

Aspergillosis Therapeutics Market by Route of Administration 

Based on route of administration, the global aspergillosis therapeutics market is divided into oral, parenteral, and others. The advantages offered by the parenteral segment help in increasing the market potential. The parenteral segment is used for drugs which are not easily absorbed. Moreover, the parenteral route of administration helps to induce a delayed response. Oral segment is expected to grow at high CAGR in the forecast period. 

Aspergillosis Therapeutics Market by Region 

Regionally, the global aspergillosis therapeutics market has been segmented into North America, Europe, Asia Pacific, and rest of the world. North America is expected to hold leading position in global aspergillosis therapeutics market. However, it is anticipated that during the forecast period, the market in Asia Pacific is likely to grow at high CAGR. The growth of North American aspergillosis therapeutics market is attributed to factors such as presence of leading market players, rising per capita healthcare expenditure, and increasing prevalence of the disease in the region. European market for aspergillus therapeutics is characterized by increased research and development activities, rising healthcare standards, and rising introduction of novel products in the region. For instance, Pfizer introduced commercial rights for CRESEMBA in 2018, which provided a new treatment for fungal infection among immunocompromised patients. Asia pacific region is anticipated to grow with high CAGR in forecast period. The region is supported by factors such as increased medical services, and easy availability of medications. 

Competitive Landscape

Some of the prominent players operating in the aspergillosis therapeutics market are 

Frequently Asked Questions About This Report

People taking immunosuppressors after certain transplant surgeries such as bone marrow and stem cell transplant increases the risk of acquiring disease. In addition, people suffering from cancer with low WBCs count are susceptible to acquire the disease. Furthermore, market players are introducing strategies such as mergers and acquisition, and introducing novel therapies to support market growth.

Some of the prominent players operating in the aspergillosis therapeutics market are Pfizer Inc., Johnson & Johnson HealthCare Systems Inc., Merck & Co. Inc., Astellas Pharma US Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Novartis International AG, Zambon SpA, and Pulmocide Ltd. among other.

The market is likely to showcase limited growth due to frequent expiration of antifungal drugs and declining prices due to increased industrial competition.

Aspergillosis is a kind of fungal disease caused by aspergillus fumigatus member of genus aspergillus. The disease most commonly affects lungs, but due time can spread to other parts of the body. Immunocompromised people are highly prone to acquire the disease.

The global aspergillosis therapeutics market was pegged at US$ 2,914.10 million in 2021 and is expected to witness a CAGR of 4.75 % during the forecast period.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trend (COVID-19 Perspective)
    2. Technological Trends
    3. Key Players & Competitive Positioning (2021)
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL ASPERGILLOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
    1. Allergic Bronchopulmonary Aspergillosis 
    2. Aspergilloma 
    3. Chronic Pulmonary Aspergillosis 
    4. Invasive Aspergillosis
    5. Others
  6. GLOBAL ASPERGILLOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Azole Antifungals 
    2. Antibiotics 
    3. Corticosteroids 
    4. Others
  7. GLOBAL ASPERGILLOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
    1. Oral 
    2. Parenteral
    3. Others
  8. GLOBAL ANTITROMBIN MARKET- ANALYSIS & FORECAST, BY REGION
    1. North America Aspergillosis Therapeutics market
      1. North America Aspergillosis Therapeutics market, by Disease Type
      2. North America Aspergillosis Therapeutics market, by Drug Class
      3. North America Aspergillosis Therapeutics market, by Route of Administration 
      4. North America Aspergillosis Therapeutics market, by Country
        1.    U.S.
          1. U.S. Aspergillosis Therapeutics market, by Disease Type
          2. U.S. Aspergillosis Therapeutics market, by Drug Class 
          3. U.S. Aspergillosis Therapeutics market, by Route of Administration 
        2. Canada
          1. Canada Aspergillosis Therapeutics market, by Disease Type
          2. Canada Aspergillosis Therapeutics market, by Drug Class 
          3. Canada Aspergillosis Therapeutics market, by Route of Administration 
    2. Europe Aspergillosis Therapeutics market
      1. Europe Aspergillosis Therapeutics market, by Disease Type
      2. Europe Aspergillosis Therapeutics market, by Drug Class
      3. Europe Aspergillosis Therapeutics market, by Route of Administration 
      4. Europe Aspergillosis Therapeutics market, by Country/Region
        1. Germany
          1. Germany Aspergillosis Therapeutics market, by Disease Type
          2. Germany Aspergillosis Therapeutics market, by Drug Class
          3. Germany Aspergillosis Therapeutics market, by Route of Administration 
        2. U.K
          1. U.K Aspergillosis Therapeutics market, by Disease Type
          2. U.K Aspergillosis Therapeutics market, by Drug Class
          3. U.K Aspergillosis Therapeutics market, by Route of Administration 
        3. France
          1. France Aspergillosis Therapeutics market, by Disease Type
          2. France Aspergillosis Therapeutics market, by Drug Class
          3. France Aspergillosis Therapeutics market, by Route of Administration 
        4. Spain
          1. Spain Aspergillosis Therapeutics market, by Disease Type
          2. Spain Aspergillosis Therapeutics market, by Drug Class
          3. Spain Aspergillosis Therapeutics market, by Route of Administration 
        5. Italy
          1. Italy Aspergillosis Therapeutics market, by Disease Type
          2. Italy Aspergillosis Therapeutics market, by Drug Class
          3. Italy Aspergillosis Therapeutics market, by Route of Administration 
        6. Rest of Europe
          1. Rest of Europe Aspergillosis Therapeutics market, by Disease Type
          2. Rest of Europe Aspergillosis Therapeutics market, by Drug Class
          3. Rest of Europe Aspergillosis Therapeutics market, by Route of Administration 
    3. Asia Pacific Aspergillosis Therapeutics market
      1. Asia Pacific Aspergillosis Therapeutics market, by Disease Type
      2. Asia Pacific Aspergillosis Therapeutics market, by Drug Class
      3. Asia Pacific Aspergillosis Therapeutics market, by Route of Administration  
      4. Asia Pacific Aspergillosis Therapeutics market, by Country/Region
        1. China
          1. China Aspergillosis Therapeutics market, by Disease Type
          2. China Aspergillosis Therapeutics market, by Drug Class
          3. China Aspergillosis Therapeutics market, by Route of Administration 
        2. Japan
          1. Japan Aspergillosis Therapeutics market, by Disease Type
          2. Japan Aspergillosis Therapeutics market, by Drug Class
          3. Japan Aspergillosis Therapeutics market, by Route of Administration 
        3. India
          1. India Aspergillosis Therapeutics market, by Disease Type
          2. India Aspergillosis Therapeutics market, by Drug Class
          3. India Aspergillosis Therapeutics market, by Route of Administration 
        4. South Korea
          1. South Korea Aspergillosis Therapeutics market, by Disease Type
          2. South Korea Aspergillosis Therapeutics market, by Drug Class
          3. South Korea Aspergillosis Therapeutics market, by Route of Administration 
        5. Australia
          1. Australia Aspergillosis Therapeutics market, by Disease Type
          2. Australia Aspergillosis Therapeutics market, by Drug Class
          3. Australia Aspergillosis Therapeutics market, by Route of Administration 
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific Aspergillosis Therapeutics market, by Disease Type
          2. Rest of Asia Pacific Aspergillosis Therapeutics market, by Drug Class
          3. Rest of Asia Pacific Aspergillosis Therapeutics market, by Route of Administration
    4. Rest of the World Aspergillosis Therapeutics market
      1. Rest of the World Aspergillosis Therapeutics market, by Disease Type
      2. Rest of the World Aspergillosis Therapeutics market, by Drug Class
      3. Rest of the World Aspergillosis Therapeutics market, by Route of Administration 
      4. Rest of the World Aspergillosis Therapeutics market, by Region
        1. Latin America
          1. Latin America Aspergillosis Therapeutics market, by Disease Type
          2. Latin America Aspergillosis Therapeutics market, by Drug Class
          3.  Latin America Aspergillosis Therapeutics market, by Route of Administration 
        2. Middle East & Africa
          1. Middle America & Africa Aspergillosis Therapeutics market, by Disease Type
          2. Middle America & Africa Aspergillosis Therapeutics market, by Drug Class
          3. Middle America & Africa Aspergillosis Therapeutics market, by Route of Administration 
  9. COMPANY PROFILE
    1. Pfizer Inc. 
      1. Business Snapshot
      2. Products Offered
      3. Financial Details*
      4. Strategic Developments
    2. Johnson & Johnson HealthCare Systems, Inc. 
    3. Merck & Co., Inc. 
    4. Astellas Pharma US, Inc. 
    5. Gilead Sciences, Inc. 
    6. GlaxoSmithKline Plc
    7. Novartis International AG
    8. Zambon SpA
    9. Pulmocide Ltd.
    10. TFF Pharmaceuticals, Inc. 

*Insights on financial performance is subject to availability of information in public domain


Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Aspergillosis Therapeutics Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Aspergillosis Therapeutics Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports